Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Bone ; 57(1): 68-75, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23891907

RESUMEN

The processes of bone resorption and bone formation are tightly coupled in young adults, which is crucial to maintenance of bone integrity. We have documented that osteoclasts secrete chemotactic agents to recruit osteoblast lineage cells, contributing to coupling. Bone formation subsequent to bone resorption becomes uncoupled with aging, resulting in significant bone loss. During bone resorption, osteoclasts release and activate transforming growth factor beta 1 (TGF-ß1) from the bone matrix; thus, elevated bone resorption increases the level of active TGF-ß in the local environment during aging. In this study, we examined the influences of TGF-ß1 on the ability of osteoclasts to recruit osteoblasts. TGF-ß1 increased osteoclast expression of the chemokine CXCL16 to promote osteoblast migration. TGF-ß1 also directly stimulated osteoblast migration; however, this direct response was blocked by conditioned medium from TGF-ß1-treated osteoclasts due to the presence of leukemia inhibitory factor (LIF) in the medium. CXCL16 and LIF expression was dependent on TGF-ß1 activation of Smad2 and Smad3. These results establish that TGF-ß1 induces CXCL16 and LIF production in osteoclasts, which modulate recruitment of osteoblasts to restore the bone lost during the resorptive phase of bone turnover.


Asunto(s)
Quimiocina CXCL6/metabolismo , Factor Inhibidor de Leucemia/metabolismo , Osteoblastos/efectos de los fármacos , Osteoclastos/efectos de los fármacos , Factor de Crecimiento Transformador beta1/farmacología , Animales , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Quimiocina CXCL16 , Quimiocina CXCL6/farmacología , Factor Inhibidor de Leucemia/genética , Ratones , Osteoblastos/citología , Osteoclastos/citología
2.
PLoS One ; 8(3): e58129, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23533582

RESUMEN

Chemokines and chemokine receptor-mediated effects are important mediators of the immunological response and cure in human leishmaniasis. However, in addition to their signalling properties for leukocytes, many chemokines have also been shown to act directly as antimicrobial peptides on bacteria and fungi. We screened ten human chemokines (CXCL2, CXCL6, CXCL8, CXCL9, CXCL10, CCL2, CCL3, CCL20, CCL27, CCL28) for antimicrobial effects on the promastigote form of the protozoan parasite Leishmania mexicana, and observed direct parasiticidal effects of several, CCL28 being the most potent. Damage to the plasma membrane integrity could be visualised by entrance of propidium iodide, as measured with flow cytometry, and by scanning electron microscopy, which showed morphological changes and aggregation of cells. The findings were in concordance with parasiticidal activity, measured by decreased mitochondrial activity in an MTT-assay. This is the first report of direct antimicrobial activity by chemokines on parasites. This component of immunity against Leishmania parasites identified here warrants further investigation that might lead to new insight in the mechanisms of human infection and/or new therapeutic approaches.


Asunto(s)
Antiinfecciosos/farmacología , Antiparasitarios/farmacología , Quimiocinas/farmacología , Leishmania mexicana/efectos de los fármacos , Péptidos/farmacología , Quimiocina CCL2/farmacología , Quimiocina CCL20/farmacología , Quimiocina CCL27/farmacología , Quimiocina CCL3/farmacología , Quimiocina CXCL10/farmacología , Quimiocina CXCL2/farmacología , Quimiocina CXCL6/farmacología , Quimiocina CXCL9/farmacología , Humanos , Interleucina-8/farmacología
3.
Antimicrob Agents Chemother ; 52(7): 2599-607, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18443119

RESUMEN

Granulocyte chemotactic protein 2 (GCP-2)/CXCL6 is a CXC chemokine expressed by macrophages and epithelial and mesenchymal cells during inflammation. Through binding and activation of its receptors (CXCR1 and CXCR2), it exerts neutrophil-activating and angiogenic activities. Here we show that GCP-2/CXCL6 itself is antibacterial. Antibacterial activity against gram-positive and gram-negative pathogenic bacteria of relevance to mucosal infections was seen at submicromolar concentrations (minimal bactericidal concentration at which 50% of strains tested were killed, 0.063 +/- 0.01 to 0.37 +/- 0.03 muM). In killed bacteria, GCP-2/CXCL6 associated with bacterial surfaces, which showed membrane disruption and leakage. A structural prediction indicated the presence of three antiparallel NH(2)-terminal beta-sheets and a short amphipathic COOH-terminal alpha-helix; the latter feature is typical of antimicrobial peptides. However, when the synthetic derivatives corresponding to the NH(2)-terminal (50 amino acids) and COOH-terminal (19 amino acids, corresponding to the putative alpha-helix) regions were compared, higher antibacterial activity was observed for the NH(2)-terminus-derived peptide, indicating that the holopeptide is necessary for full antibacterial activity. An artificial model of bacterial membranes confirmed these findings. The helical content of GCP-2/CXCL6 in the presence or absence of lipopolysaccharide or negatively charged membranes was studied by circular dichroism. As with many antibacterial peptides, membrane disruption by GCP-2/CXCL6 was dose-dependently reduced in the presence of NaCl, which, we here demonstrate, inhibited the binding of the peptide to the bacterial surface. Compared with CXC chemokines ENA-78/CXCL5 and NAP-2/CXCL7, GCP-2/CXCL6 showed a 90-fold-higher antibacterial activity. Taken together, GCP/CXCL6, in addition to its chemotactic and angiogenic properties, is likely to contribute to direct antibacterial activity during localized infection.


Asunto(s)
Antibacterianos/farmacología , Quimiocina CXCL6/farmacología , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Secuencia de Aminoácidos , Antibacterianos/química , Péptidos Catiónicos Antimicrobianos/química , Péptidos Catiónicos Antimicrobianos/farmacología , Actividad Bactericida de la Sangre , Membrana Celular/efectos de los fármacos , Quimiocina CXCL5/química , Quimiocina CXCL5/farmacología , Quimiocina CXCL6/química , Escherichia coli/efectos de los fármacos , Bacterias Gramnegativas/patogenicidad , Bacterias Grampositivas/patogenicidad , Humanos , Técnicas In Vitro , Liposomas , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Estructura Secundaria de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/farmacología , Staphylococcus aureus/efectos de los fármacos , Streptococcus pyogenes/efectos de los fármacos , beta-Tromboglobulina/química , beta-Tromboglobulina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA